Specifically, 30–60% of primary GBM patients carry EGFR amplification [9, 10], and ~ 50–60% of GBM tumors with EGFR amplification also carry constitutively active EGFR variant III (EGFRvIII) [11–13]. This evidence concerns the gene EGFR and glioblastoma.